

Susan H Eshleman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4591830/publications.pdf>

Version: 2024-02-01

170
papers

15,010
citations

46918

47
h-index

19136

118
g-index

173
all docs

173
docs citations

173
times ranked

12122
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevention of HIV-1 Infection with Early Antiretroviral Therapy. <i>New England Journal of Medicine</i> , 2011, 365, 493-505.	13.9	6,046
2	Antiretroviral Therapy for the Prevention of HIV-1 Transmission. <i>New England Journal of Medicine</i> , 2016, 375, 830-839.	13.9	1,282
3	Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 281-290.	4.6	423
4	Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). <i>Aids</i> , 2001, 15, 1951-1957.	1.0	368
5	LigAmp for sensitive detection of single-nucleotide differences. <i>Nature Methods</i> , 2004, 1, 141-147.	9.0	366
6	Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. <i>New England Journal of Medicine</i> , 2021, 385, 595-608.	13.9	359
7	Effect of Universal Testing and Treatment on HIV Incidence – HPTN 071 (PopART). <i>New England Journal of Medicine</i> , 2019, 381, 207-218.	13.9	255
8	Nevirapine (NVP) Resistance in Women with HIV-1 Subtype C, Compared with Subtypes A and D, after the Administration of Single-Dose NVP. <i>Journal of Infectious Diseases</i> , 2005, 192, 30-36.	1.9	193
9	Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis. <i>PLoS Medicine</i> , 2015, 12, e1001810.	3.9	188
10	The effect of a conditional cash transfer on HIV incidence in young women in rural South Africa (HPTN 068): a phase 3, randomised controlled trial. <i>The Lancet Global Health</i> , 2016, 4, e978-e988.	2.9	186
11	Sensitive Drug-Resistance Assays Reveal Long-Term Persistence of HIV-1 Variants with the K103N Nevirapine (NVP) Resistance Mutation in Some Women and Infants after the Administration of Single-Dose NVP: HIVNET 012. <i>Journal of Infectious Diseases</i> , 2005, 192, 24-29.	1.9	184
12	Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. <i>Lancet</i> , The, 2022, 399, 1779-1789.	6.3	177
13	Correlates of HIV Acquisition in a Cohort of Black Men Who Have Sex with Men in the United States: HIV Prevention Trials Network (HPTN) 061. <i>PLoS ONE</i> , 2013, 8, e70413.	1.1	175
14	Coreceptor Tropism in Human Immunodeficiency Virus Type 1 Subtype D: High Prevalence of CXCR4 Tropism and Heterogeneous Composition of Viral Populations. <i>Journal of Virology</i> , 2007, 81, 7885-7893.	1.5	149
15	Effect of community-based voluntary counselling and testing on HIV incidence and social and behavioural outcomes (NIMH Project Accept; HPTN 043): a cluster-randomised trial. <i>The Lancet Global Health</i> , 2014, 2, e267-e277.	2.9	141
16	Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. <i>PLoS Medicine</i> , 2018, 15, e1002690.	3.9	126
17	Concomitant Socioeconomic, Behavioral, and Biological Factors Associated with the Disproportionate HIV Infection Burden among Black Men Who Have Sex with Men in 6 U.S. Cities. <i>PLoS ONE</i> , 2014, 9, e87298.	1.1	122
18	Antiretroviral Therapies in Women after Single-Dose Nevirapine Exposure. <i>New England Journal of Medicine</i> , 2010, 363, 1499-1509.	13.9	117

#	ARTICLE	IF	CITATIONS
19	Analysis of Genetic Linkage of HIV From Couples Enrolled in the HIV Prevention Trials Network 052 Trial. <i>Journal of Infectious Diseases</i> , 2011, 204, 1918-1926.	1.9	99
20	Characterization of Nevirapine Resistance Mutations in Women With Subtype A Vs. D HIV-1 6-8 Weeks After Single-Dose Nevirapine (HIVNET 012). <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2004, 35, 126-130.	0.9	98
21	Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. <i>Lancet HIV</i> , 2020, 7, e472-e481.	2.1	97
22	Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial. <i>Lancet HIV</i> , 2018, 5, e68-e78.	2.1	96
23	HIV Incidence Determination in the United States: A Multiassay Approach. <i>Journal of Infectious Diseases</i> , 2013, 207, 232-239.	1.9	94
24	Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. <i>Aids</i> , 2005, 19, 2167-2169.	1.0	90
25	Quantitative Analysis of HIV-1 Variants With the K103N Resistance Mutation After Single-Dose Nevirapine in Women With HIV-1 Subtypes A, C, and D. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2006, 42, 610-613.	0.9	82
26	HIV Acquisition Among Women From Selected Areas of the United States. <i>Annals of Internal Medicine</i> , 2013, 158, 10.	2.0	82
27	Performance of the Celera Diagnostics ViroSeq HIV-1 Genotyping System for Sequence-Based Analysis of Diverse Human Immunodeficiency Virus Type 1 Strains. <i>Journal of Clinical Microbiology</i> , 2004, 42, 2711-2717.	1.8	78
28	Persistence of K103N-Containing HIV-1 Variants after Single-Dose Nevirapine for Prevention of HIV-1 Mother-to-Child Transmission. <i>Journal of Infectious Diseases</i> , 2007, 195, 711-715.	1.9	75
29	Infrequent HIV Testing and Late HIV Diagnosis Are Common Among a Cohort of Black Men Who Have Sex With Men in 6 US Cities. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 67, 438-445.	0.9	73
30	Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083. <i>Journal of Infectious Diseases</i> , 2021, 224, 1581-1592.	1.9	72
31	Estimation of HIV Incidence Using Multiple Biomarkers. <i>American Journal of Epidemiology</i> , 2013, 177, 264-272.	1.6	70
32	Undisclosed Antiretroviral Drug Use in a Multinational Clinical Trial (HIV Prevention Trials Network) Tj ETQq0 0 0 rgBTj/Overlock 10 Tf 50	1.9	68
33	A scalable, integrated intervention to engage people who inject drugs in HIV care and medication-assisted treatment (HPTN 074): a randomised, controlled phase 3 feasibility and efficacy study. <i>Lancet</i> , 2018, 392, 747-759.	6.3	67
34	Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial. <i>Clinical Infectious Diseases</i> , 2015, 60, 1541-1549.	2.9	65
35	Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. <i>Statistical Communications in Infectious Diseases</i> , 2017, 9, .	0.2	62
36	Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	58

#	ARTICLE	IF	CITATIONS
37	Factors Associated with Incorrect Identification of Recent HIV Infection Using the BED Capture Immunoassay. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 816-822.	0.5	57
38	Performance of a Limiting-Antigen Avidity Enzyme Immunoassay for Cross-Sectional Estimation of HIV Incidence in the United States. <i>PLoS ONE</i> , 2013, 8, e82772.	1.1	57
39	Detection of Individuals With Acute HIV-1 Infection Using the ARCHITECT HIV Ag/Ab Combo Assay. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 52, 121-124.	0.9	54
40	Treatment as Prevention: Characterization of Partner Infections in the HIV Prevention Trials Network 052 Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 112-116.	0.9	54
41	Distinct Patterns of Emergence and Fading of K103N and Y181C in Women With Subtype A vs. D After Single-Dose Nevirapine. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 40, 24-29.	0.9	52
42	Sensitivity of the ViroSeq HIV-1 Genotyping System for Detection of the K103N Resistance Mutation in HIV-1 Subtypes A, C, and D. <i>Journal of Molecular Diagnostics</i> , 2006, 8, 430-432.	1.2	52
43	Antiretroviral drug resistance, HIV-1 tropism, and HIV-1 subtype among men who have sex with men with recent HIV-1 infection. <i>Aids</i> , 2007, 21, 1165-1174.	1.0	52
44	Comparison of a High-Resolution Melting Assay to Next-Generation Sequencing for Analysis of HIV Diversity. <i>Journal of Clinical Microbiology</i> , 2012, 50, 3054-3059.	1.8	52
45	Nondisclosure of HIV Status in a Clinical Trial Setting: Antiretroviral Drug Screening Can Help Distinguish Between Newly Diagnosed and Previously Diagnosed HIV Infection. <i>Clinical Infectious Diseases</i> , 2014, 58, 117-120.	2.9	52
46	Performance of the Applied Biosystems ViroSeq Human Immunodeficiency Virus Type 1 (HIV-1) Genotyping System for Sequence-Based Analysis of HIV-1 in Pediatric Plasma Samples. <i>Journal of Clinical Microbiology</i> , 2001, 39, 1254-1257.	1.8	51
47	The development and validation of a method using high-resolution mass spectrometry (HRMS) for the qualitative detection of antiretroviral agents in human blood. <i>Clinica Chimica Acta</i> , 2014, 433, 157-168.	0.5	50
48	Nevirapine resistance after single dose prophylaxis. <i>AIDS Reviews</i> , 2002, 4, 59-63.	0.5	50
49	Performance of Applied Biosystems ViroSeq HIV-1 Genotyping System for Sequence-Based Analysis of Non-Subtype B Human Immunodeficiency Virus Type 1 from Uganda. <i>Journal of Clinical Microbiology</i> , 2001, 39, 4323-4327.	1.8	47
50	Development of Nevirapine Resistance in Infants Is Reduced by Use of Infant-Only Single-Dose Nevirapine plus Zidovudine Postexposure Prophylaxis for the Prevention of Mother-to-Child Transmission of HIV-1. <i>Journal of Infectious Diseases</i> , 2006, 193, 479-481.	1.9	46
51	Cross-Sectional HIV Incidence Estimation in HIV Prevention Research. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, S233-S239.	0.9	43
52	Use of a Multifaceted Approach to Analyze HIV Incidence in a Cohort Study of Women in the United States: HIV Prevention Trials Network 064 Study. <i>Journal of Infectious Diseases</i> , 2013, 207, 223-231.	1.9	42
53	Incorrect identification of recent HIV infection in adults in the United States using a limiting-antigen avidity assay. <i>Aids</i> , 2014, 28, 1227-1232.	1.0	42
54	Characterization of Human Immunodeficiency Virus Type 1 Populations Containing CXCR4-Using Variants from Recently Infected Individuals. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 795-802.	0.5	40

#	ARTICLE	IF	CITATIONS
55	Specificity of Four Laboratory Approaches for Cross-Sectional HIV Incidence Determination: Analysis of Samples from Adults with Known Nonrecent HIV Infection from Five African Countries. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1177-1183.	0.5	40
56	Effect of Natural and ARV-Induced Viral Suppression and Viral Breakthrough on Anti-HIV Antibody Proportion and Avidity in Patients with HIV-1 Subtype B Infection. <i>PLoS ONE</i> , 2013, 8, e55525.	1.1	40
57	Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPT. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 271-279.	0.9	40
58	A Comprehensive Genomics Solution for HIV Surveillance and Clinical Monitoring in Low-Income Settings. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	1.8	39
59	HIV testing and the HIV care continuum among sub-Saharan African men who have sex with men and transgender women screened for participation in HPTN 075. <i>PLoS ONE</i> , 2019, 14, e0217501.	1.1	38
60	Sensitivity and Specificity of the ViroSeq Human Immunodeficiency Virus Type 1 (HIV-1) Genotyping System for Detection of HIV-1 Drug Resistance Mutations by Use of an ABI PRISM 3100 Genetic Analyzer. <i>Journal of Clinical Microbiology</i> , 2005, 43, 813-817.	1.8	37
61	Antibody Maturation in Women Who Acquire HIV Infection While Using Antiretroviral Preexposure Prophylaxis. <i>Journal of Infectious Diseases</i> , 2015, 212, 754-759.	1.9	36
62	Analysis of Insertions and Deletions in the gag p6 Region of Diverse HIV Type 1 Strains. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 1119-1125.	0.5	35
63	Identification of Nevirapine-Resistant HIV-1 in the Latent Reservoir after Single-Dose Nevirapine to Prevent Mother-to-Child Transmission of HIV-1. <i>Journal of Infectious Diseases</i> , 2009, 199, 1301-1309.	1.9	35
64	Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084. <i>Journal of Infectious Diseases</i> , 2022, 225, 1741-1749.	1.9	35
65	Multi-Laboratory Comparison of Next-Generation to Sanger-Based Sequencing for HIV-1 Drug Resistance Genotyping. <i>Viruses</i> , 2020, 12, 694.	1.5	34
66	HIV-1 Tropism and Survival in Vertically Infected Ugandan Infants. <i>Journal of Infectious Diseases</i> , 2008, 197, 1382-1388.	1.9	33
67	Use of a High Resolution Melting (HRM) Assay to Compare Gag, Pol, and Env Diversity in Adults with Different Stages of HIV Infection. <i>PLoS ONE</i> , 2011, 6, e27211.	1.1	33
68	Development of Methods for Cross-Sectional HIV Incidence Estimation in a Large, Community Randomized Trial. <i>PLoS ONE</i> , 2013, 8, e78818.	1.1	33
69	Predictors of Early and Late Mother-to-Child Transmission of HIV in a Breastfeeding Population: HIV Network for Prevention Trials 012 Experience, Kampala, Uganda. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 52, 32-39.	0.9	32
70	Impact of Maternal and Infant Antiretroviral Drug Regimens on Drug Resistance in HIV-infected Breastfeeding Infants. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, e164-e169.	1.1	31
71	Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women. <i>Annals of Internal Medicine</i> , 2017, 167, 384.	2.0	29
72	Estimation of HIV Incidence in a Large, Community-Based, Randomized Clinical Trial: NIMH Project Accept (HIV Prevention Trials Network 043). <i>PLoS ONE</i> , 2013, 8, e68349.	1.1	28

#	ARTICLE	IF	CITATIONS
73	Comprehensive Profiling of HIV Antibody Evolution. <i>Cell Reports</i> , 2019, 27, 1422-1433.e4.	2.9	27
74	Identification of Ugandan HIV Type 1 Variants with Unique Patterns of Recombination in pol Involving Subtypes A and D. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 507-511.	0.5	26
75	Identification and validation of a multi-essay algorithm for cross-sectional HIV incidence estimation in populations with subtype C infection. <i>Journal of the International AIDS Society</i> , 2018, 21, e25082.	1.2	26
76	Nevirapine Resistance in Women and Infants after First versus Repeated Use of Single-Dose Nevirapine for Prevention of HIV-1 Vertical Transmission. <i>Journal of Infectious Diseases</i> , 2008, 198, 465-469.	1.9	25
77	Use of single-dose nevirapine for the prevention of mother-to-child transmission of HIV-1: does development of resistance matter?. <i>American Journal of Obstetrics and Gynecology</i> , 2007, 197, S56-S63.	0.7	24
78	Analysis of <i>pol</i> Integrase Sequences in Diverse HIV Type 1 Strains Using a Prototype Genotyping Assay. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 343-345.	0.5	24
79	Analysis of HIV Diversity Using a High-Resolution Melting Assay. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 913-918.	0.5	24
80	HIV-1 Transmission during Early Antiretroviral Therapy: Evaluation of Two HIV-1 Transmission Events in the HPTN 052 Prevention Study. <i>PLoS ONE</i> , 2013, 8, e71557.	1.1	24
81	Analysis of HIV Using a High Resolution Melting (HRM) Diversity Assay: Automation of HRM Data Analysis Enhances the Utility of the Assay for Analysis of HIV Incidence. <i>PLoS ONE</i> , 2012, 7, e51359.	1.1	21
82	Antiretroviral Drug Use and HIV Drug Resistance Among HIV-Infected Black Men Who Have Sex With Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, 446-452.	0.9	21
83	Phenotypic Drug Resistance Patterns in Subtype A HIV-1 Clones with Nonnucleoside Reverse Transcriptase Resistance Mutations. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 289-293.	0.5	20
84	HIV Type 1 Polymerase Gene Polymorphisms Are Associated With Phenotypic Differences in Replication Capacity and Disease Progression. <i>Journal of Infectious Diseases</i> , 2014, 209, 66-73.	1.9	20
85	Brief Report: Impact of Early Antiretroviral Therapy on the Performance of HIV Rapid Tests and HIV Incidence Assays. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 426-430.	0.9	20
86	Virologic outcomes in early antiretroviral treatment: HPTN 052. <i>HIV Clinical Trials</i> , 2017, 18, 100-109.	2.0	20
87	Limited Evolution in the HIV Type 1 <i>pol</i> Region among Acute Seroconverters in Pune, India. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 93-97.	0.5	19
88	Comparison of HIV-1 Mother-to-Child Transmission After Single-Dose Nevirapine Prophylaxis Among African Women With Subtypes A, C, and D. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 42, 518-521.	0.9	19
89	Addition of extended zidovudine to extended nevirapine prophylaxis reduces nevirapine resistance in infants who were HIV-infected in utero. <i>Aids</i> , 2010, 24, 381-386.	1.0	19
90	HIV Diversity as a Biomarker for HIV Incidence Estimation: Including a High-Resolution Melting Diversity Assay in a Multiassay Algorithm. <i>Journal of Clinical Microbiology</i> , 2014, 52, 115-121.	1.8	19

#	ARTICLE	IF	CITATIONS
91	Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis. <i>Aids</i> , 2011, 25, 911-917.	1.0	18
92	Impact of Mutation Type and Amplicon Characteristics on Genetic Diversity Measures Generated Using a High-Resolution Melting Diversity Assay. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 130-137.	1.2	18
93	Accuracy of Self-Reported HIV Status Among African Men and Transgender Women Who Have Sex with Men Who were Screened for Participation in a Research Study: HPTN 075. <i>AIDS and Behavior</i> , 2019, 23, 289-294.	1.4	18
94	Phylogenetic Methods Inconsistently Predict the Direction of HIV Transmission Among Heterosexual Pairs in the HPTN 052 Cohort. <i>Journal of Infectious Diseases</i> , 2019, 220, 1406-1413.	1.9	18
95	Association between the Replication Capacity and Mother-to-Child Transmission of HIV-1, in Antiretroviral Drug-Naive Malawian Women. <i>Journal of Infectious Diseases</i> , 2006, 193, 1512-1515.	1.9	17
96	Emergence and persistence of nevirapine resistance in breast milk after single-dose nevirapine administration. <i>Aids</i> , 2010, 24, 557-561.	1.0	17
97	Failure to Identify HIV-Infected Individuals in a Clinical Trial Using a Single HIV Rapid Test for Screening. <i>HIV Clinical Trials</i> , 2014, 15, 62-68.	2.0	17
98	Comparison of cross-sectional HIV incidence assay results from dried blood spots and plasma. <i>PLoS ONE</i> , 2017, 12, e0172283.	1.1	17
99	Detection of K103N in Ugandan women after repeated exposure to single dose nevirapine. <i>Aids</i> , 2007, 21, 2077-2082.	1.0	16
100	Comparison of LigAmp and an ASPCR Assay for Detection and Quantification of K103N-Containing HIV Variants. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 595-605.	0.5	16
101	A Comparison of Two Measures of HIV Diversity in Multi-Assay Algorithms for HIV Incidence Estimation. <i>PLoS ONE</i> , 2014, 9, e101043.	1.1	16
102	Comparison of Antibody Responses to HIV Infection in Ugandan Women Infected with HIV Subtypes A and D. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 421-427.	0.5	16
103	Evaluation of Phylogenetic Methods for Inferring the Direction of Human Immunodeficiency Virus (HIV) Transmission: HIV Prevention Trials Network (HPTN) 052. <i>Clinical Infectious Diseases</i> , 2021, 72, 30-37.	2.9	16
104	Association of HIV Diversity and Survival in HIV-Infected Ugandan Infants. <i>PLoS ONE</i> , 2011, 6, e18642.	1.1	16
105	Antiretroviral drug susceptibility among drug-naive adults with recent HIV infection in Rakai, Uganda. <i>Aids</i> , 2009, 23, 845-852.	1.0	15
106	Immune Responses in Ugandan Women Infected With Subtypes A and D HIV Using the BED Capture Immunoassay and an Antibody Avidity Assay. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 390-396.	0.9	15
107	Evaluation of a Multidrug Assay for Monitoring Adherence to a Regimen for HIV Preexposure Prophylaxis in a Clinical Study, HIV Prevention Trials Network 073. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	15
108	Antiretroviral drug use and HIV drug resistance among MSM and transgender women in sub-Saharan Africa. <i>Aids</i> , 2018, 32, 1301-1306.	1.0	15

#	ARTICLE	IF	CITATIONS
109	Analysis of Drug Resistance in Children Receiving Antiretroviral Therapy for Treatment of HIV-1 Infection in Uganda. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 563-568.	0.5	14
110	Use of Antiretroviral Drug Testing to Assess the Accuracy of Self-reported Data from HIV-Infected People Who Inject Drugs. <i>AIDS and Behavior</i> , 2019, 23, 2101-2108.	1.4	14
111	HIV incidence in a multinational cohort of men and transgender women who have sex with men in sub-Saharan Africa: Findings from HPTN 075. <i>PLoS ONE</i> , 2021, 16, e0247195.	1.1	14
112	Short Communication:HIV Type 1 Variants with Nevirapine Resistance Mutations Are Rarely Detected in Antiretroviral Drug-Naive African Women with Subtypes A, C, and D. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 764-768.	0.5	13
113	Antiretroviral Drug Susceptibility Among HIV-Infected Adults Failing Antiretroviral Therapy in Rakai, Uganda. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1739-1744.	0.5	13
114	Regional differences between people who inject drugs in an <sc>HIV</sc> prevention trial integrating treatment and prevention (<sc>HPTN</sc> 074): a baseline analysis. <i>Journal of the International AIDS Society</i> , 2018, 21, e25195.	1.2	13
115	Performance of a high-throughput next-generation sequencing method for analysis of HIV drug resistance and viral load. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3510-3516.	1.3	13
116	Comparison of mother-to-child transmission rates in Ugandan women with subtype A versus D HIV-1 who received single-dose nevirapine prophylaxis: HIV Network For Prevention Trials 012. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 39, 593-7.	0.9	13
117	Use of a High Resolution Melting Assay to Analyze HIV Diversity in HIV-infected Ugandan Children. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, e222-e228.	1.1	12
118	HIV-1 diversity among young women in rural South Africa: HPTN 068. <i>PLoS ONE</i> , 2018, 13, e0198999.	1.1	12
119	Short- and Long-Term Pharmacologic Measures of HIV Pre-exposure Prophylaxis Use Among High-Risk Men Who Have Sex With Men in HPTN 067/ADAPT. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 149-158.	0.9	12
120	The feasibility of recruiting and retaining men who have sex with men and transgender women in a multinational prospective HIV prevention research cohort study in sub-Saharan Africa (HPTN 075). <i>Journal of the International AIDS Society</i> , 2020, 23, e25600.	1.2	12
121	Highly multiplexed oligonucleotide probe-ligation testing enables efficient extraction-free SARS-CoV-2 detection and viral genotyping. <i>Modern Pathology</i> , 2021, 34, 1093-1103.	2.9	12
122	Comparison of Laboratory Methods for Analysis of Non-nucleoside Reverse Transcriptase Inhibitor Resistance in Ugandan Infants. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 657-663.	0.5	11
123	Low-Level Viremia Early in HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, 405-408.	0.9	11
124	HIV drug resistance in persons who inject drugs enrolled in an HIV prevention trial in Indonesia, Ukraine, and Vietnam: HPTN 074. <i>PLoS ONE</i> , 2019, 14, e0223829.	1.1	11
125	Under-Reporting of Known HIV-Positive Status Among People Living with HIV: A Systematic Review and Meta-analysis. <i>AIDS and Behavior</i> , 2021, 25, 3858-3870.	1.4	11
126	The Effect of Sample Handling on Cross Sectional HIV Incidence Testing Results. <i>PLoS ONE</i> , 2011, 6, e25899.	1.1	11

#	ARTICLE	IF	CITATIONS
127	HIV Drug Resistance in Adults Receiving Early vs. Delayed Antiretroviral Therapy: HPTN 052. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 77, 484-491.	0.9	10
128	Analysis of HIV-1 variants by cloning DNA generated with the ViroSeq™ HIV-1 Genotyping System. <i>BioTechniques</i> , 2003, 35, 614-622.	0.8	9
129	Analysis of HIV Type 1 gp41 Sequences in Diverse HIV Type 1 Strains. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1593-1598.	0.5	9
130	Short Communication: Comparison of Maxim and Sedia Limiting Antigen Assay Performance for Measuring HIV Incidence. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 555-557.	0.5	9
131	Impact of Early Antiretroviral Treatment Initiation on Performance of Cross-Sectional Incidence Assays. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 583-589.	0.5	9
132	Brief Report: Hormonal Contraception Use and Cabotegravir Pharmacokinetics in HIV-Uninfected Women Enrolled in HPTN 077. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2020, 85, 93-97.	0.9	9
133	Antiretroviral Drug Use in a Cohort of HIV-Uninfected Women in the United States: HIV Prevention Trials Network 064. <i>PLoS ONE</i> , 2015, 10, e0140074.	1.1	8
134	Antiretroviral Drug Use in a Cross-Sectional Population Survey in Africa. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 74, 158-165.	0.9	8
135	Determination of HIV status and identification of incident HIV infections in a large, community-randomized trial: HPTN 071 (PopART). <i>Journal of the International AIDS Society</i> , 2020, 23, e25452.	1.2	8
136	Survival of Ugandan Infants with Subtype A and D HIV-1 Infection (HIVNET 012). <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 31, 327-330.	0.9	7
137	Analysis of HIV Type 1 gp41 and Enfuvirtide Susceptibility among Men in the United States Who Were HIV Infected Prior to Availability of HIV Entry Inhibitors. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 701-705.	0.5	7
138	Pregnancy Does Not Affect HIV Incidence Test Results Obtained Using the BED Capture Enzyme Immunoassay or an Antibody Avidity Assay. <i>PLoS ONE</i> , 2010, 5, e13259.	1.1	7
139	HIV Surveillance in a Large, Community-Based Study: Results from the Pilot Study of Project Accept (HIV Prevention Trials Network 043). <i>BMC Infectious Diseases</i> , 2011, 11, 251.	1.3	7
140	Antibody Maturation and Viral Diversification in HIV-Infected Women. <i>PLoS ONE</i> , 2013, 8, e57350.	1.1	7
141	Association of pol Diversity with Antiretroviral Treatment Outcomes among HIV-Infected African Children. <i>PLoS ONE</i> , 2013, 8, e81213.	1.1	7
142	Determination of HIV Status in African Adults With Discordant HIV Rapid Tests. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2015, 69, 430-438.	0.9	7
143	Development and Evaluation of a Modified Fourth-Generation Human Immunodeficiency Virus Enzyme Immunoassay for Cross-Sectional Incidence Estimation in Clade B Populations. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 756-762.	0.5	7
144	Short Communication: The Impact of Viral Suppression and Viral Breakthrough on Limited-Antigen Avidity Assay Results in Individuals with Clade B HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 325-327.	0.5	7

#	ARTICLE	IF	CITATIONS
145	Performance of the BioPlex 2200 HIV Ag-Ab assay for identifying acute HIV infection. <i>Journal of Clinical Virology</i> , 2018, 99-100, 67-70.	1.6	7
146	Human Immunodeficiency Virus (HIV) Drug Resistance, Phylogenetic Analysis, and Superinfection Among Men Who Have Sex with Men and Transgender Women in Sub-Saharan Africa: HIV Prevention Trials Network (HPTN) 075 Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 60-67.	2.9	7
147	High levels of resistance to nucleoside/nucleotide reverse transcriptase inhibitors in newly diagnosed antiretroviral treatment-naïve children in sub-Saharan Africa. <i>Aids</i> , 2020, 34, 1567-1570.	1.0	7
148	Validation of population-level HIV-1 incidence estimation by cross-sectional incidence assays in the HPTN 071 (PopART) trial. <i>Journal of the International AIDS Society</i> , 2021, 24, e25830.	1.2	7
149	Evaluation of multi-assay algorithms for identifying individuals with recent HIV infection: HPTN 071 (PopART). <i>PLoS ONE</i> , 2021, 16, e0258644.	1.1	7
150	Performance of the fourth-generation Bio-Rad GS HIV Combo Ag/Ab enzyme immunoassay for diagnosis of HIV infection in Southern Africa. <i>Journal of Clinical Virology</i> , 2015, 62, 75-79.	1.6	6
151	Analysis of HIV Integrase Resistance in Black Men Who Have Sex with Men in the United States. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 745-748.	0.5	6
152	Phylogenetic Analysis of Human Immunodeficiency Virus from People Who Inject Drugs in Indonesia, Ukraine, and Vietnam: HPTN 074. <i>Clinical Infectious Diseases</i> , 2020, 71, 1836-1846.	2.9	6
153	HIV Antibody Profiles in HIV Controllers and Persons With Treatment-Induced Viral Suppression. <i>Frontiers in Immunology</i> , 2021, 12, 740395.	2.2	6
154	Genetic Linkage of Nevirapine Resistance Mutations in HIV Type 1 Seven Days after Single-Dose Nevirapine. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 319-324.	0.5	4
155	Analysis of Nevirapine Resistance Mutations in Cloned HIV Type 1 Variants from HIV-Infected Ugandan Infants Using a Single-Step Amplification-Sequencing Method (AmpliSeq). <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 1209-1213.	0.5	4
156	Antiretroviral Drug Use and HIV Drug Resistance Among Young Women in Rural South Africa: HPTN 068. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 315-322.	0.9	4
157	Natural control of HIV infection in young women in South Africa: HPTN 068. <i>HIV Clinical Trials</i> , 2018, 19, 202-208.	2.0	4
158	Short Communication: Dried Blood Spots Stored at Room Temperature Should Not Be Used for HIV Incidence Testing. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 1013-1016.	0.5	4
159	Uptake of antiretroviral treatment and viral suppression among men who have sex with men and transgender women in sub-Saharan Africa in an observational cohort study: HPTN 075. <i>International Journal of Infectious Diseases</i> , 2021, 104, 465-470.	1.5	4
160	Antiretroviral drug use and HIV drug resistance in female sex workers in Tanzania and the Dominican Republic. <i>PLoS ONE</i> , 2020, 15, e0240890.	1.1	4
161	Analysis of HIV Diversity in HIV-Infected Black Men Who Have Sex with Men (HPTN 061). <i>PLoS ONE</i> , 2016, 11, e0167629.	1.1	3
162	Antiretroviral Therapy to Prevent HIV Acquisition: Limits of Estimation From a Population Cohort. <i>Clinical Infectious Diseases</i> , 2016, 63, 1679-1680.	2.9	3

#	ARTICLE	IF	CITATIONS
163	A top scoring pairs classifier for recent HIV infections. <i>Statistics in Medicine</i> , 2021, 40, 2604-2612.	0.8	3
164	Association of HIV diversity and virologic outcomes in early antiretroviral treatment: HPTN 052. <i>PLoS ONE</i> , 2017, 12, e0177281.	1.1	3
165	An improved HIV antigen/antibody prototype assay for earlier detection of acute HIV infection. <i>Journal of Clinical Virology</i> , 2021, 145, 105022.	1.6	3
166	HIV drug resistance in a communityâ€randomized trial of universal testing and treatment: HPTN 071 (PopART). <i>Journal of the International AIDS Society</i> , 2022, 25, .	1.2	3
167	CXCR4-using HIV variants in a cohort of Black men who have sex with men: HIV Prevention Trials Network 061. <i>HIV Clinical Trials</i> , 2016, 17, 158-164.	2.0	1
168	Characteristics Associated With Human Immunodeficiency Virus Transmission Networks Involving Adolescent Girls and Young Women in Human Immunodeficiency Virus Prevention Trials Network 068 Study. <i>Sexually Transmitted Diseases</i> , 2019, 46, e46-e49.	0.8	1
169	Short Communication: Viral Genetic Linkage Analysis Among Black Men Who Have Sex With Men (HIV) Tj ETQq1 1 0,784314 rgBT /Ove	0.5	1
170	Engaging People Who Inject Drugs Living With HIV in Antiretroviral Treatment and Medication for Opioid Use Disorder: Extended Follow-up of HIV Prevention Trials Network (HPTN) 074. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab281.	0.4	1